Tuesday, April 02, 2019 2:24:32 PM
MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma
MD Anderson News Release April 01, 2019
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.
MZL is a low-grade non-Hodgkin lymphoma that accounts for 6 percent of all lymphoma diagnoses. Although it is treatable, many patients relapse, at which point few treatment options exist.
“Umbralisib is part of a new class of drugs that are quite active in low-grade lymphomas,” said Fowler. “These PI3K inhibitors have shown activity across a spectrum of low-grade lymphomas and are effective in shutting down some of the key signaling that is occurring with MZL.”
The research team reported 55 percent of patients who had at least six months of follow-up had a partial or complete response after receiving umbralisib, a small-molecule inhibitor that targets a signaling pathway linked to MZL cell growth and expansion. Felipe Samaniego, M.D., associate professor in Lymphoma & Myeloma, was co-lead for the study.
The trial enrolled 69 patients, with 38 patients responding favorably and progression-free survival was 71 percent after one year. The patients received umbralisib orally once a day.
“This study is ongoing and we have yet to reach a median duration of response, although most of the patients who received the drug remain in remission,” said Fowler.
The average MZL patient is diagnosed at about age 60 and is typically treated with a monoclonal antibody called rituximab either alone or in combination with chemotherapy.
“This disease is initially quite treatable with several good options for patients that result in high response rates,” said Fowler. “Unfortunately, for about 70 percent of these patients, relapse occurs and there are limited treatment options at that time. That relapse can occur within a year or it can take several years, but most patients will eventually stop responding to standard treatment.”
Fowler added that his team was specifically looking at patients who had failed several standard treatment options including chemotherapy or monoclonal antibodies. He is encouraged that there are several novel therapies for less common lymphomas such as MZL.
“At MD Anderson, we have been fortunate to lead the development of several of these targeted drugs in lymphoma,” he said. “Phase I studies conducted here with PI3K and BTK inhibitors has now resulted in Food and Drug Administration approval of many of these drugs across several types of lymphoma.”
Other institutions who participated in the study included Jagiellonian University, Krakow, Poland; the Institute of Hematology and Transfusion Medicine, Warsaw; Levine Cancer Institute, Charlotte, N.C.; the Sarah Cannon Research Institute, Chattanooga, Tenn.; King’s College Hospital NHS Foundation Trust, London; the Sara Cannon Research/Florida Cancer Specialists, Fort Myers, Fla.; John Theurer Cancer Center, Hackensack, N.J.; Copernicus Memorial Hospital, Lodz, Poland; Moffitt Cancer Center, Tampa, Fla.; Universitá Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan; European Institute of Oncology, Milan; Rocky Mountain Cancer Center, Aurora, Colo.; Willamette Valley Cancer Institute, Eugene, Ore.; Compass Oncology, Vancouver, Wash.; Columbia University Medical Center, New York; Sir Charles Gairdner Hospital, Perth, Australia; TG Therapeutics, Inc., New York; and University of Bologna, Italy.
The study was funded by TG Therapeutics. Fowler serves on the scientific advisory board for TG Therapeutic. A complete list of disclosures is available in the AACR abstract.
https://www.mdanderson.org/newsroom/single-agent-umbralisib-effective-for-relapsed-slow-growing-lymphoma.h00-159301467.html?cmpid=twitter_newsroom_lymphoma_clinicaltrials
Recent TGTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 08:59:11 PM
- TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 04/30/2024 08:55:29 PM
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/15/2024 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 03/01/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 10:23:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:24:56 PM
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy) • GlobeNewswire Inc. • 02/27/2024 12:30:00 PM
- TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy) • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2024 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 02:53:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:30:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 12:37:35 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
- Biotech Massively Bid Up Before Opening Bell • AllPennyStocks.com • 01/09/2024 02:20:00 PM
- TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases • GlobeNewswire Inc. • 01/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:33:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:32:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:00:59 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM